TARRYTOWN, N.Y.--Emisphere Technologies, Inc. (“Emisphere”, NASDAQ: EMIS) announced today results from its 90-day, Phase 2 study of its oral insulin product utilizing its eligen® oral delivery technology. The four-arm study evaluated the safety and efficacy of low and high fixed doses of oral insulin tablets versus placebo in patients with Type 2 Diabetes Mellitus on existing oral metformin monotherapy. The trial focused on the safety of oral insulin, specifically noting incidents of hypoglycemia, as well as the occurrence of insulin antibodies. The study met the Company’s objectives for both safety and efficacy.
The eligen technology is basically a packaging mechanism as a drug carrier:
"Drug molecules exist in many different shapes, or conformations. Some conformations can be transported across the cell membranes while others are too large or too charged to do so. The eligen technology uses the body’s natural passive transcellular transport process to enable large or highly charged molecules to cross cell membranes. Once the drug molecule crosses the membrane, the EMISPHERE delivery agent dissociates from the drug molecule, which then reestablishes its natural conformation and returns to its therapeutically active state."
EMIS closed down 24% today to $6.77- ouch.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment